Previous 10 | Next 10 |
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, has been named a 2021 Healthcare Businesswomen’s Association (HBA) Luminary. Dr. Thompson will be honored at the 2021 HBA Woman of the ...
Image source: The Motley Fool. Horizon Therapeutics PLC (NASDAQ: HZNP) Q1 2021 Earnings Call May 5, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Horizon Therapeutics PLC (HZNP) Q1 2021 Earnings Call Transcript
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2021 Q1 earnings call. For further details see: Horizon Therapeutics Public Limited Company 2021 Q1 - Results - Earnings Call Presentation
Horizon Therapeutics Public Limited Company (HZNP) Q1 2021 Earnings Conference Call May 5, 2021 8:00 AM ET Company Participants Tina Ventura – Senior Vice President of Investor Relations Tim Walbert – Chairman, President and Chief Executive Officer Paul Hoelscher – Execut...
Horizon Therapeutics (HZNP) has revised its full-year net sales and adjusted EBITDA guidance upwards to reflect its acquisition of Viela Bio that closed in March.Net sales are now expected to be between $2.75B to $2.85B, and adjusted EBITDA between $1.02B and $1.06B.For the quarter, Horizon b...
Horizon Therapeutics (HZNP): Q1 Non-GAAP EPS of $0.03 misses by $0.02; GAAP EPS of -$0.55 misses by $0.03.Revenue of $342.4M (-3.8% Y/Y) beats by $1.67M.Adjusted gross margin rate of 90.9% vs. consensus of 88.1%.The company now expects FY2021 net sales to range between $2.75B-$2.85B increased...
-- First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million -- -- First-Quarter 2021 Orphan Segment Net Sales Increased 5 Percent to $257.5 Million; KRYSTEXXA ® (pegloticase injection) First-Q...
Horizon Therapeutics (NASDAQ:HZNP) is scheduled to announce Q1 earnings results on Wednesday, May 5th, before market open.The consensus EPS Estimate is $0.05 (-87.5% Y/Y) and the consensus Revenue Estimate is $340.73M (-4.3% Y/Y).Over the last 2 years, HZNP has beaten EPS estimates 100% of th...
-- In its inaugural year on the survey, Horizon had top rankings in integrity, patient information and services among patient groups partnering with the company -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #4 in overall corporate reputation among...
HemoShear Therapeutics has identified a second gout drug candidate as part of its collaboration with Horizon Therapeutics (HZNP).HemoShear leveraged its proprietary REVEAL-Tx disease modeling platform in the discovery.Under a January 2019 agreement, HemoShear received an upfront payment and R...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...